NEWS
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
Alector (Nasdaq: ALEC) presented baseline characteristics for its pivotal INFRONT-3 Phase 3 clinical trial at the 14th International Conference on Frontotemporal Dementias. The trial evaluates latozinemab, a novel monoclonal antibody, for treating frontotemporal dementia with progranulin gene mutation (FTD-GRN). Key points:
- 119 participants enrolled (103 symptomatic, 16 at-risk carriers)
- Mean age: 62.1 years
- 51.3% female, 84.9% Caucasian
- Symptomatic cohort mean CDR plus NACC FTLD-SB score: 6.9
- Mean serum neurofilament light chain: 73.0 pg/mL
The baseline characteristics suggest a representative study population, enabling effective testing of latozinemab in FTD-GRN. The trial, completed enrollment in October 2023, is ongoing with a 96-week treatment duration.
Alector (Nasdaq: ALEC) presented baseline characteristics for its pivotal INFRONT-3 Phase 3 clinical trial at the 14th International Conference on Frontotemporal Dementias. The trial evaluates latozinemab, a novel monoclonal antibody, for treating frontotemporal dementia with progranulin gene mutation (FTD-GRN). Key points:
- 119 participants enrolled (103 symptomatic, 16 at-risk carriers)
- Mean age: 62.1 years
- 51.3% female, 84.9% Caucasian
- Symptomatic cohort mean CDR plus NACC FTLD-SB score: 6.9
- Mean serum neurofilament light chain: 73.0 pg/mL
The baseline characteristics suggest a representative study population, enabling effective testing of latozinemab in FTD-GRN. The trial, completed enrollment in October 2023, is ongoing with a 96-week treatment duration.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2542Followers
107Following
28KVisitors
Follow